Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.76 |
| ▸ | CA2 | P00918 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | TP53 | P04637 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795960 | 0.87 | CA2 (1.00) | CA1CA2MAPTTP53RAB9A | |
| SCHEMBL2664519 | 0.76 | SMN1; SMN2 (0.67) | CA1CA2MAPTTP53RAB9A | |
| SCHEMBL11480689 | 0.76 | CSNK2A2 (0.83) | TP53RAB9ANPC1SMN1; SMN2SRC | |
| SCHEMBL10991652 | 0.76 | GLS (0.72) | CA1CA2MAPTTP53RAB9A | |
| SCHEMBL7485532 | 0.75 | SMN1; SMN2 (0.65) | CA1CA2MAPTTP53RAB9A | |
| SCHEMBL2664586 | 0.74 | GCK (0.46) | CA1CA2MAPTTP53RAB9A | |
| SCHEMBL31060226 | 0.74 | NPC1 (1.00) | RAB9ANPC1POLBLMNASMN1; SMN2 | |
| SCHEMBL11473324 | 0.73 | TP53 (0.66) | CA1CA2TP53RAB9ANPC1 | |
| SCHEMBL3974838 | 0.72 | CA1 (0.78) | CA1CA2THRBSMN1; SMN2CA4 | |
| SCHEMBL14316971 | 0.72 | CA1 (0.78) | CA1CA2MAPTTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| EP-1568367-B1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | CA1 1388/4885CA2 540/4885MAPT 4022/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | CA1 1388/4885CA2 540/4885MAPT 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.